argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-11-04)

EUR 815.00+3.32%

argenx SE
UMushroom community rating:

4.92 4 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

11.0%1Y

75.0%3Y

186%5Y

Performance

34.8%1Y

38.8%3Y

39.2%5Y

Volatility

57196 M

Market cap (USD)

170,174

Daily traded volume (Shares)

600 / 594.2

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.92

4 votes

Performance:

4.42

Innovation:

4.58

Society:

4.50

Nature:

3.75

William Tanex

UK, 26 Oct 2026

good bet for their earning calls, even though it came earlier than expected

Laura Sofie Tohver

UK, 11 Nov 2025

Emerging technology and nice returns

Viktor Stockel

Switzerland, 30 Oct 2025

Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.

EQUITIES OF THE SAME SECTOR

Alphabet Inc

Alphabet Inc Valor: 29798545

Annual Return

-50%0%+50%

Risk level

110

1.31%USD 291.08

Schneider Electric SE

Schneider Electric SE Valor: 509120

Annual Return

-50%0%+50%

Risk level

110

0.90%EUR 233.63

Wipro Limited

Wipro Limited Valor: 1006385

Annual Return

-50%0%+50%

Risk level

110

-1.95%INR 193.75

Zensar Technologies Limited

Zensar Technologies Limited Valor: 43200200

Annual Return

-50%0%+50%

Risk level

110

-0.05%INR 532.95

Data Patterns (India) Limited

Data Patterns (India) Limited Valor: 115413439

Annual Return

-50%0%+50%

Risk level

110

3.47%INR 4,082.00

EnerSys Inc

EnerSys Inc Valor: 1865089

Annual Return

-50%0%+50%

Risk level

110

-7.12%USD 156.00

ASML Holding NV

ASML Holding NV Valor: 19531091

Annual Return

-50%0%+50%

Risk level

110

-3.42%EUR 1,312.00

Black Box Limited

Black Box Limited Valor: 118606432

Annual Return

-50%0%+50%

Risk level

110

1.23%INR 808.05

net digital AG

net digital AG Valor: 35045378

Annual Return

-50%0%+50%

Risk level

110

-2.05%EUR 28.60

Paychex Inc

Paychex Inc Valor: 960724

Annual Return

-50%0%+50%

Risk level

110

2.65%USD 118.71

SIX

FactSet

Clearbit

Logos provided by Clearbit